InnoCan Pharma Corporation reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 4.08 million compared to USD 0.749 million a year ago. Net loss was USD 2.03 million compared to USD 0.168 million a year ago. Basic loss per share from continuing operations was USD 0.007 compared to USD 0.001 a year ago. Diluted loss per share from continuing operations was USD 0.007 compared to USD 0.001 a year ago.
For the nine months, sales was USD 8.76 million compared to USD 1.42 million a year ago. Net loss was USD 3.82 million compared to USD 2.56 million a year ago. Basic loss per share from continuing operations was USD 0.014 compared to USD 0.011 a year ago.